Shrestha Suja, Yan Elaine, Yang Beining, Blundell Aled, Teng Allen C T, Marks Ryan M, Cohn Ronald, Ivakine Evgueni, Gramolini Anthony O, Santerre J Paul
Faculty of Dentistry, University of Toronto, Toronto, Ontario M5G 1G6, Canada; Translational Biology and Engineering Program and Ted Rogers Centre for Heart Research, Toronto, Ontario M5G 1M1, Canada.
Translational Biology and Engineering Program and Ted Rogers Centre for Heart Research, Toronto, Ontario M5G 1M1, Canada.
Acta Biomater. 2025 Jun 14. doi: 10.1016/j.actbio.2025.06.017.
Developing safe and effective biomaterials to deliver RNA into cells has grown in importance over recent years and has enabled the clinical translation of several gene therapies. Self-assembled oligo-urethane nanoparticles (PNPs) have several advantageous properties, such as (1) mitigating immune cell response in vivo, (2) low cytotoxicity in a broad range of cells, and (3) capable of delivering oligonucleotides or proteins into cells. Here, we were interested in defining unique configurations of PNPs to assess their relative cytotoxicity to human cells, comparing them to a popular commercial lipid system MessengerMax, as some cationic lipids have been found to have associated toxicity, instigating the search for less toxic counterparts. This was then followed by demonstrating the ability of enhanced green fluorescent protein (EGFP) mRNA to be loaded onto the PNPs, and to establish methods to enable the efficient transgene expression in a number of cell types, including Caco-2 and CC cells which are known to be difficult-to-transfect cells. The addition of small amounts of PEGylated lipid to PNP significantly increased EGFP expression in HEK293T cells, Caco-2 cells and CC cells at an effective mRNA/PNPs ratio (wt/wt) of 1:40, while the addition of the ionizable cationic lipid, significantly increased EGFP expression in CC cells and differentiated CC cells (myofibers) at mRNA/PNPs ratio (wt/wt) of 1:125, while keeping PNPs mass constant to 62.5 μg and changing the mRNA mass. Our study demonstrated that lipid-assisted, PNP-mediated mRNA delivery achieved a high transfection efficiency in terminally differentiated myofibers, paving the way for potential innovative therapeutics, e.g. targeted to muscular dystrophies. STATEMENT OF SIGNIFICANCE: There are reports of diverse delivery agents for RNA, but there is still unmet need for more versatile, and safe delivery vehicles. In this study we demonstrated that when compared to MessengerMax (a lipid-based mRNA transfection reagent), self-assembled oligo-urethane nanoparticle (PNP) showed favorable cell viability. The scope of PNP as a RNA delivery vehicle was extended beyond HEK293T cells by showing transfections into a number of cell types. The addition of select lipids to PNPs, significantly increased EGFP expression in difficult-to-transfect cells: Caco-2 (2.9-fold), CC (1.4-fold) and differentiated CC (1.28-fold) cells when compared to PNPs. These findings indicate that select lipid incorporation on PNPs provide a promising strategy to improve the efficacy of RNA therapeutics for diseases in clinical applications.
近年来,开发安全有效的生物材料将RNA递送至细胞的重要性日益凸显,并推动了多种基因疗法的临床转化。自组装寡聚聚氨酯纳米颗粒(PNP)具有多种优势特性,例如:(1)减轻体内免疫细胞反应;(2)在多种细胞中具有低细胞毒性;(3)能够将寡核苷酸或蛋白质递送至细胞内。在此,我们旨在确定PNP的独特结构,以评估其对人类细胞的相对细胞毒性,并将其与一种广受欢迎的商业脂质系统MessengerMax进行比较,因为已发现一些阳离子脂质具有相关毒性,从而促使人们寻找毒性更低的替代物。随后,我们展示了增强型绿色荧光蛋白(EGFP)mRNA加载到PNP上的能力,并建立了在多种细胞类型中实现高效转基因表达的方法,包括已知难以转染的Caco-2细胞和CC细胞。在有效的mRNA/PNP比例(重量/重量)为1:40时,向PNP中添加少量聚乙二醇化脂质可显著提高HEK293T细胞、Caco-2细胞和CC细胞中的EGFP表达;而添加可电离阳离子脂质,在mRNA/PNP比例(重量/重量)为1:125时,可显著提高CC细胞和分化的CC细胞(肌纤维)中的EGFP表达,同时保持PNP质量恒定为62.5μg并改变mRNA质量。我们的研究表明,脂质辅助的PNP介导的mRNA递送在终末分化的肌纤维中实现了高转染效率,为潜在的创新疗法(如针对肌肉萎缩症的疗法)铺平了道路。重要性声明:有关于多种RNA递送剂的报道,但对于更通用、安全的递送载体仍有未满足的需求。在本研究中,我们证明,与MessengerMax(一种基于脂质的mRNA转染试剂)相比,自组装寡聚聚氨酯纳米颗粒(PNP)显示出良好的细胞活力。通过展示在多种细胞类型中的转染,将PNP作为RNA递送载体的范围扩展到了HEK293T细胞之外。与PNP相比,向PNP中添加特定脂质可显著提高难转染细胞(Caco-2细胞提高2.9倍、CC细胞提高1.4倍、分化的CC细胞提高1.28倍)中的EGFP表达。这些发现表明,在PNP上掺入特定脂质为提高RNA疗法在临床应用中治疗疾病的疗效提供了一种有前景的策略。